News headlines about FibroGen (NASDAQ:FGEN) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 48.3562026723734 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- FibroGen Inc (FGEN) Director Thomas F. Kearns, Jr. Sells 18,000 Shares (americanbankingnews.com)
- Brokerages Anticipate FibroGen Inc (FGEN) Will Post Quarterly Sales of $28.23 Million (americanbankingnews.com)
- FibroGen Inc (FGEN) Director Sells $1,276,953.75 in Stock (americanbankingnews.com)
- Brokerages Expect FibroGen Inc (FGEN) Will Post Earnings of -$0.51 Per Share (americanbankingnews.com)
- FibroGen Inc (FGEN) VP Sells $100,609.28 in Stock (americanbankingnews.com)
A number of equities research analysts have recently issued reports on FGEN shares. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. TheStreet raised shares of FibroGen from a “d” rating to a “c-” rating in a report on Tuesday, February 27th. Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Finally, Leerink Swann restated an “outperform” rating and issued a $88.00 price objective (up previously from $80.00) on shares of FibroGen in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $66.67.
In other news, insider K Peony Yu sold 10,000 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $62.00, for a total transaction of $620,000.00. Following the sale, the insider now directly owns 152,086 shares in the company, valued at $9,429,332. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Pat Cotroneo sold 49,500 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $55.96, for a total value of $2,770,020.00. Following the completion of the sale, the vice president now owns 207,392 shares in the company, valued at $11,605,656.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 448,237 shares of company stock valued at $23,351,636. Company insiders own 13.60% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.